The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.
Author: The Medical News
Kenneth D. Steinsapir receives rare USPTO patent for Microdroplet BOTOX
Kenneth D. Steinsapir, M.D., has been issued a rare patent (US 7,846,457 B2) by The United States Patent and Trademark Office for the invention of a breakthrough method for administering cosmetic botulinum toxin. The patent for Microdroplet botulinum t…
Ifa Systems acquires inoveon
ifa Systems AG, the global leader for IT solutions in ophthalmology based in Cologne, Germany, announced the acquisition of inoveon Corporation, proven experts in detection, staging, and monitoring of diabetic retinopathy and macular edema.
Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease
Alkeus Pharmaceuticals and Columbia University announced today that they have entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerati…
PanOptica completes $30 million Series A financing
PanOptica, Inc., a private biopharmaceutical company focused on licensing and developing innovative ophthalmology therapies, today announced that it has raised $30 million in a Series A financing. This round was led by SV Life Sciences and Third Rock V…
Lyophilized amniotic membrane in strabismus surgery can cause severe fibrosis
Postoperative adhesions are a major complication in strabismus surgery. Amniotic membrane has been used in the hopes of preventing these adhesions by forming a biological barrier during healing. In an article in the December 2010 issue of the Journal o…
Los Angeles Magazine declares LA BioMed physicians as 2011 Southern California Super Doctors
A select 40 physician-researchers at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center were named 2011 Southern California Super Doctors in the January issue of Los Angeles Magazine.
FDA clears ACT’s IND to treat AMD using hESC derived RPE cells
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to treat Dry Age-Related Macular Degener…
NEI awards Case Western Reserve $10M for study of retinal diseases
The Departments of Pharmacology and Ophthalmology and Visual Sciences at Case Western Reserve University School of Medicine have been awarded a $10.1 million grant from the National Eye Institute (NEI) to research and develop new treatments for disease…
Santen files IND for Clinical Data’s ATL313 for primary open angle glaucoma and ocular hypertension
Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data’s highly selective adenosine A2A agonist, ATL313, for …
Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company’s drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. T…
NextGen Healthcare announces partnership with Wills Eye for meaningful use
NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, and leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Wills Eye Health System to deploy NextGen® Ambul…
NinePoint enters IP licensing agreement with Massachusetts General Hospital
NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology medical devices, today announced it has entered into an intellectual property (IP) licensing agreement with Massachusetts General Hospital (MGH). Under the agreement, N…
Vision community, FDA discuss use of PROs to improve labeling of ophthalmic treatments, products
The vision community is discussing with the Food and Drug Administration how vision-related patient-reported outcomes might be used in improving the labeling of ophthalmic treatments and products. The group — composed of researchers, clinicians, poli…
Calhoun Vision LAL Light Adjustable Lens for customized cataract surgery
Vision RejuvenationTM Victoria, a Canadian leader in advanced cataract and refractive lens exchange surgery has become the first centre in Canada to implant the world’s first Light Adjustable Intraocular Lens.
Closer to restoring vision loss due to optic nerve damage
Damage to the optic nerve, connecting the eye with the brain, is a major cause of blindness. The most common culprit is glaucoma, estimated to affect more than 4 million Americans. There is currently no way to restore the lost vision, because the optic…
FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band
Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee has recommended with an 8-2 vote that the FDA extend the currently approved use …
ACT files IND application to initiate Phase I/II study for Dry AMD
Advanced Cell Technology, Inc. announced today that it has filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using human embryonic stem cell (hESC) derived reti…
QOI and Quantel enter co-promotion agreement for Activis PDT Lasers
QLT Inc. today announced that its wholly-owned U.S. subsidiary, QLT Ophthalmics, Inc. (“QOI”), and Quantel Medical and its distributor, Quantel USA, Inc., have entered into a co-promotion agreement for the sale of Activis PDT Lasers used to activate Vi…
USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.